Search results for "From ACP Journal Club"
In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps
A challenge to wider use of the open-source systems to manage type 1 diabetes (T1DM) is that they are not approved by the FDA and thus require clinicians to be willing to learn from and support their patients, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2023/01/13/9.htm
13 Jan 2023
In prediabetes, oral vitamin D reduces progression to new-onset diabetes
Other preventive treatments for patients with prediabetes may be more effective than this review found vitamin D to be, but vitamin supplementation has advantages of convenience, tolerability, availability, and cost over other options, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/8.htm
12 May 2023
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2022/10/14/6.htm
14 Oct 2022
In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control
Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
https://diabetes.acponline.org/archives/2022/03/11/7.htm
11 Mar 2022
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/01/11/6.htm
11 Jan 2019
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/05/13/6.htm
13 May 2022
In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia
A reduction in hyperkalemia could allow use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or aldosterone-receptor blockers in at-risk patients, justifying the prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/09/16/6.htm
16 Sep 2022
Some glucose-lowering drugs reduce risk for major adverse cardiac events
An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
https://diabetes.acponline.org/archives/2020/08/14/7.htm
14 Aug 2020